Patent intelligence · US
US 8106082
Dual-acting antihypertensive agents
Dual-acting antihypertensive agents
Patent details — US 8106082
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2012
- Expiration
- Jan 26, 2032
- Applicant
- Theravance, Inc.
- Claims
- 22
- CPC classes
- A61P, A61P43/00, A61P9/00, A61P9/04
Quick answer
US 8106082 (Dual-acting antihypertensive agents) is held by Theravance, Inc.. Status: granted. Granted Jan 31, 2012. Expires Jan 26, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61P, A61P43/00, A61P9/00, A61P9/04, A61P9/12
More from Theravance, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8106082?
US 8106082 (Dual-acting antihypertensive agents) is held by Theravance, Inc.. Status: granted. Granted Jan 31, 2012. Expires Jan 26, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8106082?
Theravance, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8106082 expire?
Our index shows an expiration date of Jan 26, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.